Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

  • October 12, 2026

  • 3 min

Share

  • 1

    Caribou Biosciences plans to discontinue its two allogeneic CAR T-cell programs and substantially reduce its workforce after failing to secure development funding.

  • 2

    The company’s board is reviewing strategic alternatives, including a merger, acquisition, business combination, or transaction involving Caribou or its assets.

  • 3

    Caribou reported $113.8 million in cash, cash equivalents, and marketable securities on June 30, after previously projecting funds through the end of 2027.

  • 4

    Vispa-cel, an anti-CD19 therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, was ready to enter a pivotal phase 3 trial, while CB-011 targets multiple myeloma.

  • 5

    The workforce reduction is expected to be largely completed in the fourth quarter of 2026, and CEO Rachel Haurwitz said she hoped another organization would continue the programs.

Original Source(s)

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

  • October 12, 2026

Related Content

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min
Daily-life dynamics of general and cognitive fatigue in childhood cancer survivors: An experience sampling and wearable study